Author

J. W. Chen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Assay:proteomics· 1

Frequent Co-Authors

A. E. Nibbs· 1 shared A. Kirov· 1 shared B. A. Tannous· 1 shared B. D. Cosgrove· 1 shared C. C. da Hora· 1 shared c. E. badr· 1 shared E. Fitzsimons· 1 shared E. Tabet· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. E. Nibbs

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Chemoresistance to additive PARP/PI3K dual inhibition in triple-negative breast cancer cell lines is associated with adaptive stem cell-like prevalence

P. E. Petrella, J. W. Chen, G. O. Ravelo, B. D. Cosgrove

This study examines the chemoresistance of triple-negative breast cancer cell lines to PARP/PI3K dual inhibition and identifies treatment schedules that enhance its efficacy.

bioRxiv · Apr 28, 2024 · PreprintCancer Biology

Obtusaquinone is a cysteine modifying compound that targets Keap1 for degradation

c. E. badr, C. C. da Hora, A. Kirov, R. Amante, E. Fitzsimons, J. W. Chen, A. E. Nibbs, I. Nakano, E. Tabet, N. Chiu, W. Haas, R. Mazitschek, B. A. Tannous

This study identifies Obtusaquinone as a cysteine-modifying compound that targets Keap1 for degradation, activating the Nrf2 pathway through proteasomal degradation.

ACS Chemical Biology · Apr 27, 2020Peer-reviewedCancer Biology